" class="no-js "lang="en-US"> Cambrian Bio Appoints VP of Global Policy and Strategic Initiatives
Monday, February 26, 2024

Cambrian Bio Appoints Health Policy Veteran Adrienne Hallett as Vice President of Global Policy and Strategic Initiatives

Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, today announces the appointment of Adrienne Hallett as Vice President of Global Policy and Strategic Initiatives. In this new role, Hallett will be working with foundations, government institutions and other groups for investment into Cambrian Bio’s pipeline and gaining approval to launch primary prevention trials.

Hallett has over 25 years of health policy experience at the highest levels of the US government. She previously served as the Associate Director for Legislative Policy and Analysis for the National Institutes of Health, the world’s largest funder of biomedical research, where she garnered congressional support to launch national initiatives including the All of Us Research Program, the Cancer MoonshotSM, and the Helping to End Addiction Long-term® Initiative, among others. She briefly served as an advisor to the Biden White House on the establishment of ARPA-H and the launch of a national initiative to eliminate Hepatitis C. Prior to that, she served on the Appropriations Committee of the US Senate as a lead negotiator for funding of public health and research programs. She has drafted dozens of US health laws, including portions of the Affordable Care Act relating to prevention policies and programs. She holds a master’s degree in theological studies from Vanderbilt Divinity School with a concentration in ethics.

In this role, Hallett will lead Cambrian Bio’s efforts to create markets for preventive pharmaceuticals by developing strategic partnerships with key stakeholders and advocate for shifts in global public and private payment policies related to healthy longevity. Hallett will engage across Cambrian Bio’s operations and companies to envision and implement product-specific strategies designed to increase the availability of Cambrian Bio’s products worldwide. This includes early-stage de-risking approaches and post-approval marketing to third party payers. This role will report directly to the Chief Executive Officer, James Peyer.

“Preventing and treating diseases of aging is of paramount importance for the economies of the world, but mostly for the daily struggles of the families affected,” said Hallett. “Ensuring government policies keep pace with science gives individuals as well as their families the gift of time. I’m thrilled to be joining the Cambrian Bio team and to help them continue to utilize cutting edge technologies to prove the age-old maxim that an ounce of prevention is worth a pound of cure.”

“I’m honored that Adrienne has chosen to join us at Cambrian Bio in this new role and will be able to provide her valuable insights regarding policy and our strategic initiatives moving forward as an organization,” said James Peyer, PhD, CEO of Cambrian Bio. “This is a very important milestone for the company as we continue to evolve and forge our path to successfully treat and prevent the chronic diseases of aging.”

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more